TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32074418

Group type: EXPERIMENTAL
Intervention: Nemolizumab (0.5 mg/kg, subcutaneously at baseline, week 4, and week 8)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nemolizumab
Number of subjects: 70
Study: 34582636

Group type: EXPERIMENTAL
Intervention: Unani formulation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hydroquinone 4% (Control)
Number of subjects: 72
Study: 33649972

Group type: EXPERIMENTAL
Intervention: 2-week spa therapy with low-dose radon therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2-week spa therapy without radon therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (with and without radon therapy)
Number of subjects: 25
Study: 32065766

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 17922

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 17922
Study: 35866644

Group type: EXPERIMENTAL
Intervention: Experimental schedule group (n=192) reviewed in a reduced-frequency schedule
Number of subjects: 388

Group type: COMPARATOR
Intervention: Conventional schedule group (control: n=196) reviewed as per current national guidelines
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Experimental schedule group (n=192)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Conventional schedule group (control: n=196)
Number of subjects: 388
Study: 34544847

Group type: EXPERIMENTAL
Intervention: TipsByText intervention, 3 times a week for 7 months
Number of subjects: 644
Study: 32299999

Group type: EXPERIMENTAL
Intervention: Baduanjin training (60 min per session, 3 sessions per week for 24 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual physical activity control group (health education for 30 min at least once a month)
Number of subjects: 102
Study: 34495379

Group type: EXPERIMENTAL
Intervention: Nomogram prediction model based on parametrium invasion, lymph node metastasis, and oviduct metastasis.
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Nomogram prediction model
Number of subjects: 1496
Study: 33821958

Group type: EXPERIMENTAL
Intervention: Pharmacist-led, mHealth-based intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study: 36280642

Group type: EXPERIMENTAL
Intervention: Crofelemer 125 mg orally twice daily during chemotherapy cycles 1 and 2
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no scheduled prophylactic medication)
Number of subjects: 51
Study: 33197084

Group type: EXPERIMENTAL
Intervention: 'Chronically relapsing brain disease'
Number of subjects: 3635

Group type: COMPARATOR
Intervention: 'Problem' (control)
Number of subjects: 3635

Group type: EXPERIMENTAL
Intervention: Gender comparison (male vs female)
Number of subjects: 3635
Study: 32934365

Group type: EXPERIMENTAL
Intervention: Novel anticancer agents and combination therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent or combination therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple agents in a head-to-head comparison
Number of subjects: 0
Study: 32037096

Group type: EXPERIMENTAL
Intervention: Sublingual (SL) administration of edaravone 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous (IV) infusion of edaravone 60 mg
Number of subjects: 0
Study: 34923134

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 33058438

Group type: EXPERIMENTAL
Intervention: Phenytoin (4-6 mg/kg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 32487575

Group type: EXPERIMENTAL
Intervention: Eco-directed sustainable prescribing (EDSP)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: EDSP practices
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: EDSP and EPV awareness
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Attitudes towards EDSP
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Low-dose prescribing and environment-friendly drug profiles
Number of subjects: 405
Study: 33315716

Group type: EXPERIMENTAL
Intervention: High perirenal fat surface area (fourth quartile)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Perirenal fat surface area (cm² increase)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Perirenal fat surface area categories
Number of subjects: 733
Study: 33176887

Group type: EXPERIMENTAL
Intervention: Durvalumab plus bevacizumab (10 mg/kg each i.v.)
Number of subjects: 26
Study: 35843115

Group type: EXPERIMENTAL
Intervention: Neuro-linguistic programming (NLP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33554299

Group type: EXPERIMENTAL
Intervention: Digitally assisted vitreoretinal system (DAVS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional analog microscope (CAM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both DAVS and CAM
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DAVS
Number of subjects: 60

Group type: COMPARATOR
Intervention: CAM
Number of subjects: 60
Study: 33534791

Group type: EXPERIMENTAL
Intervention: MB66 film (Active)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo film (Control)
Number of subjects: 38
Study: 32008572

Group type: EXPERIMENTAL
Intervention: Electric toothbrush with a monitor to visualise red‐fluorescent dental plaque (monitor usage group, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Electric toothbrush without a monitor (monitor‐non‐use group, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of monitor usage group vs monitor non-use group
Number of subjects: 20
Study: 35556386

Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg/daily for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 10
Study: 32512067

Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Positive control (no medicament)
Number of subjects: 38
Study: 35639828

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 828

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 828
Study: 33563235

Group type: COMPARATOR
Intervention: DePuy Synthes® one‐third semitubular plate (Group I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: NEWCLIP TECHNICS, Active Ankle® polyaxial locking plate (Group II)
Number of subjects: 45
Study: 33132656

Group type: EXPERIMENTAL
Intervention: Particulate matter with a diameter ≤ 2.5 μm (PM2.5)
Number of subjects: 20071900

Group type: EXPERIMENTAL
Intervention: Carbon monoxide (CO)
Number of subjects: 20071900

Group type: EXPERIMENTAL
Intervention: Average temperature
Number of subjects: 20071900

Group type: EXPERIMENTAL
Intervention: Air pollutants
Number of subjects: 20071900

Group type: EXPERIMENTAL
Intervention: Time lag of MFAPs exposure
Number of subjects: 20071900
Study: 34446476

Group type: EXPERIMENTAL
Intervention: Administration of oxytocin
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Male sex of the neonate
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Primigravidity
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Meconium-stained liquor
Number of subjects: 720
Study: 32869813

Group type: EXPERIMENTAL
Intervention: Test breakfasts with increasing viscosity of konjac glucomannan (KGM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control treatment (one of the four test breakfasts)
Number of subjects: 22
Study: 35781080

Group type: EXPERIMENTAL
Intervention: SNAP-Ed intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 33506447

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroids (cumulative 4-5 g) + orbital irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bony orbital decompression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teprotumumab (IGF-1 receptor antibody)
Number of subjects: 0
Study: 32191722

Group type: COMPARATOR
Intervention: Oxytocin administration (24 IU)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Conditioned oxytocin (24 IU with CS during acquisition days, placebo with CS during evocation days)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 35238041

Group type: EXPERIMENTAL
Intervention: NSPT with 1% melatonin gel
Number of subjects: 22

Group type: COMPARATOR
Intervention: NSPT with placebo gel
Number of subjects: 22
Study: 34121140

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day for 1 week, then 6 mg/day for 7 weeks)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (identical to melatonin)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 32208439

Group type: EXPERIMENTAL
Intervention: Bisoprolol (beta-blocker)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor antagonist
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 32487568

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 0
Study: 36156195

Group type: EXPERIMENTAL
Intervention: Bilateral anodal tDCS stimulation over left and right cerebellar hemispheres, 10 sessions (20-min duration, five sessions per week)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 36
Study: 33370571

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (2000 mg)
Number of subjects: 45
Study: 33067293

Group type: EXPERIMENTAL
Intervention: Happy House intervention (six weekly 90 min school-based group sessions)
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Usual curriculum (control group)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Happy House intervention
Number of subjects: 1204
Study: 37732870

Group type: EXPERIMENTAL
Intervention: ESM with personalized feedback (ESM-f)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ESM alone (ESM)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no additional intervention)
Number of subjects: 124
Study: 33667406

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 460

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 460
Study: 32769877

Group type: EXPERIMENTAL
Intervention: Oral probiotics (3 months duration)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Diet and exercise therapy (control group)
Number of subjects: 140
Study: 34808006

Group type: EXPERIMENTAL
Intervention: Erythritol air polishing (test group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Saline-soaked cotton gauzes (control group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study: 32161056

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: History of breast cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen treatment for breast cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aromatase inhibitors treatment for breast cancer
Number of subjects: 0
Study: 35727103

Group type: EXPERIMENTAL
Intervention: Heart Failure Worsening (HFW)
Number of subjects: 12753
Study: 32100634

Group type: EXPERIMENTAL
Intervention: Self-compassion induction (educational prompts and compassionate perspective writing)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control condition (verbal learning only)
Number of subjects: 141
Study: 35292492

Group type: EXPERIMENTAL
Intervention: Fast-track referral for early intervention on psychosocial and behavioural risk factors (smoking, alcohol consumption, depression, physical violence)
Number of subjects: 2832

Group type: COMPARATOR
Intervention: Local standard of care for risk factors
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: Fast-track referral for early intervention
Number of subjects: 2832
Study: 34897651

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 32
Study: 33004384

Group type: EXPERIMENTAL
Intervention: Behavioural intervention package to support clinicians and patients to amend incorrect penicillin allergy records.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural intervention package materials developed based on barriers identified.
Number of subjects: 0
Study: 35599320

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 418

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 418
Study: 33650758

Group type: EXPERIMENTAL
Intervention: TAK-020
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 35470582

Group type: EXPERIMENTAL
Intervention: TightRope® system
Number of subjects: 18

Group type: COMPARATOR
Intervention: TightRope®
Number of subjects: 18

Group type: COMPARATOR
Intervention: IS screw
Number of subjects: 18
Study: 32770730

Group type: EXPERIMENTAL
Intervention: AZD4831 15 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: AZD4831 45 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: AZD4831
Number of subjects: 13
Study: 32546973

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg alone once daily for seven days (Period I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg with linagliptin 20 mg for seven days (Period II)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Linagliptin 20 mg alone once daily for seven days (Period I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Linagliptin 20 mg with fimasartan 120 mg for seven days (Period II)
Number of subjects: 36
Study: 33290915

Group type: EXPERIMENTAL
Intervention: SLIT plus pharmacotherapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 111
Study: 32925028

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication for agitation related to dementia
Number of subjects: 801

Group type: COMPARATOR
Intervention: Non-pharmacological therapy
Number of subjects: 801
Study: 35294524

Group type: EXPERIMENTAL
Intervention: Immediate cryotherapy (Arm A)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Cytology-based screening (Arm B)
Number of subjects: 288
Study: 32958459

Group type: EXPERIMENTAL
Intervention: BioMatrix stents
Number of subjects: 2341

Group type: COMPARATOR
Intervention: Orsiro stents
Number of subjects: 2341
Study: 35956288

Group type: EXPERIMENTAL
Intervention: Whey-protein plus glucose (240 kcal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose (120 kcal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Whey-protein (120 kcal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (2 kcal)
Number of subjects: 20
Study: 34377456

Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation (RFD) for low back pain
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Recommendations on the RFD technique
Number of subjects: 14
Study: 35344191

Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide 1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-daily canagliflozin 300 mg
Number of subjects: 0
Study: 32234610

Group type: EXPERIMENTAL
Intervention: Parental communication about alcohol
Number of subjects: 269
Study: 35089070

Group type: EXPERIMENTAL
Intervention: Nasal swab with vibration (Tc group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nasal swab without vibration (Ct group)
Number of subjects: 34
Study: 34406248

Group type: EXPERIMENTAL
Intervention: Interlaminar technique
Number of subjects: 55

Group type: COMPARATOR
Intervention: Transforaminal technique
Number of subjects: 55
Study: 33211508

Group type: EXPERIMENTAL
Intervention: Malleable mindset intervention
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Social norms intervention
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Combination of malleable mindset and social norms
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 292
Study: 35113595

Group type: EXPERIMENTAL
Intervention: Research‐to‐Policy Collaboration (RPC) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33982202

Group type: EXPERIMENTAL
Intervention: CNN-based segmentation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 49
Study: 33711209

Group type: EXPERIMENTAL
Intervention: ACT OPEN
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 38
Study: 32648534

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 120
Study: 34030219

Group type: EXPERIMENTAL
Intervention: Acupressure at the p6 point for 10 minutes in both hands, twice a day for two consecutive days.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Inactive acupressure at the thumb hands at the same time points as the intervention group.
Number of subjects: 64
Study: 36247107

Group type: EXPERIMENTAL
Intervention: Gait Resistance Training (GRT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Stability Resistance Training (SRT)
Number of subjects: 26
Study: 32705703

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) with minimal support
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 12
Study: 35100190

Group type: EXPERIMENTAL
Intervention: Short storage RBCs (stored for up to seven days)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard issue RBCs
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Transfused patients
Number of subjects: 146
Study: 34330457

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (1 g/day) for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (corn starch) for 12 weeks
Number of subjects: 43
Study: 35791031

Group type: EXPERIMENTAL
Intervention: LASSO-derived nomogram
Number of subjects: 1883
Study: 35665279

Group type: EXPERIMENTAL
Intervention: Narrative nursing combined with thinking map health education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Narrative nursing
Number of subjects: 60
Study: 32375747

Group type: EXPERIMENTAL
Intervention: Regular, low-dose (≤32 mg/day), sustained-release morphine for chronic breathlessness associated with COPD
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 35347300

Group type: EXPERIMENTAL
Intervention: Daily tadalafil plus early low-intensity shock wave therapy (LI-SWT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Daily tadalafil only
Number of subjects: 80
Study: 33598702

Group type: EXPERIMENTAL
Intervention: Storybook about home hazards (intervention group, N=29)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Storybook about healthy eating (control group, N=30)
Number of subjects: 59
Study: 32320842

Group type: EXPERIMENTAL
Intervention: Early intensive treatment approach using one of four monoclonal antibodies as initial therapy.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Escalation treatment approach using any other approved medication as initial therapy with subsequent escalation to higher efficacy treatments.
Number of subjects: 400
Study: 34368905

Group type: EXPERIMENTAL
Intervention: Ipsilateral ST graft harvest
Number of subjects: 140

Group type: COMPARATOR
Intervention: Contralateral ST graft harvest
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 34970881

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with thunder‐fire moxibustion
Number of subjects: 94

Group type: COMPARATOR
Intervention: Acupuncture alone (Control group)
Number of subjects: 94
Study: 34509329

Group type: EXPERIMENTAL
Intervention: Hybrid hyrax (HH) expander
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional hyrax (CH) expander
Number of subjects: 40
Study: 35023564

Group type: EXPERIMENTAL
Intervention: Messaging on mortality effects of VLNC cigarettes
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Messaging on morbidity or mortality effects of VLNC cigarettes
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 1177
Study: 35477046

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Hydrogen peroxide
Number of subjects: 4
Study: 35960897

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Conventional Radiation Therapy (CRT)
Number of subjects: 279
Study: 33123718

Group type: EXPERIMENTAL
Intervention: Controlled reoxygenation (normoxia)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hyperoxic CPB
Number of subjects: 90
Study: 32785490

Group type: COMPARATOR
Intervention: Non-inferiority experimental group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-inferiority margin determination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sample size calculation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Data final analysis
Number of subjects: 0
Study: 35929037

Group type: EXPERIMENTAL
Intervention: Combination of Dexmedetomidine (Dex) and Butorphanol (But)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Dexmedetomidine (Dex)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Butorphanol (But)
Number of subjects: 208
Study: 36469353

Group type: EXPERIMENTAL
Intervention: Goal-directed incentives
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Outcome-based incentives
Number of subjects: 668

Group type: COMPARATOR
Intervention: Resources-only group
Number of subjects: 668
Study: 33887240

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 200
Study: 33041028

Group type: EXPERIMENTAL
Intervention: Nucleotide supplementation (2 g/d)
Number of subjects: 20
Study: 616503306

Group type: EXPERIMENTAL
Intervention: Therapy-related factors (patient-rated pretreatment credibility and early therapeutic alliance)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Self-transcendence
Number of subjects: 56